← Back to Analyst Consensus 
BCAX Buy
Bicara Therapeutics Inc.
Current Price —
Implied Upside —
Analysts 20
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 17, 2026 (22 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 19, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Aug 19, 2026 | BMO Capital | initiate | — → Outperform | — | 53% |
| Aug 12, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| Aug 12, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Aug 12, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Aug 12, 2026 | Mizuho | maintain | Neutral → Neutral | — | 52% |
| Aug 12, 2026 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Aug 12, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| May 12, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| May 12, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| May 11, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Mar 31, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| Mar 31, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Mar 31, 2026 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Mar 31, 2026 | Citizens | reiterate | Market Outperform → Market Outperform | — | 46% |
| Mar 31, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 25, 2026 | B of A Securities | initiate | — → Buy | — | 53% |
| Jan 29, 2026 | Citizens | initiate | — → Market Outperform | $31 | 46% |
| Jan 13, 2026 | Wedbush | reiterate | Outperform → Outperform | $30 | 58% |
| Jan 8, 2026 | BTIG | initiate | — → Buy | $28 | 52% |
| Dec 18, 2025 | Mizuho | initiate | — → Neutral | $18 | 52% |
| Nov 11, 2025 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $11 | 54% |
| Aug 22, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $40 | 44% |
| Aug 19, 2025 | Piper Sandler | initiate | — → Overweight | $36 | 54% |
| May 23, 2025 | Wells Fargo | upgrade | Underweight → Equal-Weight | $8 | 54% |
| May 16, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $41 | 44% |
| Apr 17, 2025 | Wells Fargo | initiate | — → Underweight | $8 | 54% |
| Apr 7, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $44 | 44% |
| Mar 13, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $13.01 | 50% |
| Feb 12, 2025 | Wedbush | reiterate | Outperform → Outperform | $31 | 58% |
| Feb 6, 2025 | Wedbush | initiate | — → Outperform | $31 | 58% |
| Jan 27, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $45 | 44% |
| Dec 6, 2024 | HC Wainwright & Co. | initiate | — → Buy | $42 | 44% |
| Oct 8, 2024 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Oct 8, 2024 | Stifel | initiate | — → Buy | $47 | 53% |
| Oct 8, 2024 | Morgan Stanley | initiate | — → Overweight | $35 | 54% |
| Oct 8, 2024 | TD Cowen | initiate | — → Buy | $0 | 54% |
Price Target Trend
May 26, 2026 Oct 26, 2026
EPS Estimates
0q —
+1y —
0y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days